- Report
- September 2025
- 138 Pages
Global
From €5265EUR$5,950USD£4,511GBP
- Report
- August 2025
- 150 Pages
Global
From €5265EUR$5,950USD£4,511GBP
- Report
- June 2026
- 145 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- June 2026
- 149 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- April 2026
- 146 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- April 2026
- 135 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- April 2026
- 150 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- March 2026
- 147 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- March 2026
- 150 Pages
Global
From €2654EUR$2,999USD£2,274GBP
€3538EUR$3,999USD£3,032GBP
- Report
- May 2026
- 188 Pages
Global
From €3982EUR$4,500USD£3,412GBP
- Report
- August 2026
- 318 Pages
Global
From €2212EUR$2,500USD£1,896GBP
- Report
- August 2026
- 309 Pages
Global
From €2212EUR$2,500USD£1,896GBP
- Report
- June 2026
- 341 Pages
Global
From €2212EUR$2,500USD£1,896GBP
- Report
- August 2026
- 299 Pages
Global
From €5176EUR$5,850USD£4,436GBP
- Report
- August 2026
- 278 Pages
Global
From €5176EUR$5,850USD£4,436GBP
- Report
- August 2026
- 462 Pages
Global
From €5176EUR$5,850USD£4,436GBP
- Report
- August 2026
- 194 Pages
Global
From €5176EUR$5,850USD£4,436GBP
- Report
- August 2026
- 197 Pages
Global
From €3137EUR$3,545USD£2,688GBP
€3485EUR$3,939USD£2,987GBP
- Report
- August 2026
- 189 Pages
Global
From €3137EUR$3,545USD£2,688GBP
€3485EUR$3,939USD£2,987GBP
- Report
- August 2026
- 196 Pages
Global
From €3137EUR$3,545USD£2,688GBP
€3485EUR$3,939USD£2,987GBP

The Companion Diagnostics market is a subset of the biotechnology industry that focuses on the development and commercialization of diagnostic tests that are used to identify patients who are likely to benefit from a particular therapeutic. These tests are used to identify the presence of a specific biomarker or genetic mutation that is associated with a particular therapeutic. The Companion Diagnostics market is driven by the increasing demand for personalized medicine, which is tailored to the individual patient's genetic makeup. This has led to the development of more sophisticated tests that can detect a wider range of biomarkers and mutations.
The Companion Diagnostics market is highly competitive, with a number of companies offering a range of tests. Examples of companies in the market include Roche Diagnostics, Abbott Laboratories, Qiagen, Illumina, and Thermo Fisher Scientific. Show Less Read more